Scientists test Radiation-Immunotherapy combo for rare bone cancer
NCT ID NCT02989636
Summary
This early-stage safety study is testing a combination treatment for chordoma, a rare bone cancer that has come back or spread. Researchers want to see if adding a targeted, high-dose radiation treatment to an immunotherapy drug (nivolumab) is safe and tolerable. The study involves a small group of patients to first understand the side effects before testing if the combination helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHORDOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.